Mehdi Najafzadeh, PhD, MSc, MA
Brigham & Women’s Hospital
Department of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
1620 Tremont Street, Suite 3030,
Boston, MA 02120
Phone: 617-278-0934 | Fax: 617-232-8602
Mehdi Najafzadeh PhD, MSc, MA, is an Instructor in Medicine at Harvard Medical School and an associate statistician/epidemiologist in the Division of Pharmacoepidemiology and Phamacoeconomics at the Brigham and Women’s Hospital.
His research involves measuring and comparing benefits, risks, and cost of drugs and health care interventions in general. In particular, evaluation of clinical and economic outcomes of genomic medicine and development of methods for risk benefit analysis of drugs have been his main research areas. His methodological interests include modeling and simulation, preference elicitation techniques using choice experiments, and statistical modeling.
Dr. Najafzadeh was awarded a fellowship from Canadian Institutes of Health Research (CIHR) while he was a post-doctoral fellow at Harvard Medical School. He received his doctorate in health economics from the University of British Columbia (UBC) where he was a CIHR Canada Graduate Scholar and recipient of a Four-Year Fellowship from UBC. He has an MA in Economics from UBC, an M.Sc. in Socio-Economic Systems, and B.Sc. in Electrical Engineering from Sharif University of Technology, Tehran.
Selected Publications | Current PubMed Search Results
- Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C. Ann Intern Med. (In press)
- Najafzadeh M, Schneeweiss S, Choudhry NK, Bykov K, Kahler KH, Martin DP, Gagne JJ. A unified framework for classification of methods for benefit-risk assessment. Value in Health (In Press).
- Najafzadeh M, Gagne JJ, Choudhry NK, Polinski JM, Avorn J, Schneeweiss SS. Patients’ preferences in anticoagulant therapy: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):912-9.
- Ungar WJ, Hadioonzadeh A, Najafzadeh M, Tsao NW, Dell S, Lynd LD. Quantifying preferences for asthma control in parents and adolescents using best-worst scaling. Respir Med. 2014 Jun; 108(6):842-51.
- Shields AE, Najafzadeh M, Schachter AB. Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatment. Per Med. 2013 Nov 1;10(8). doi: 10.2217/pme.13.89.
- Najafzadeh M, Johnston KM, Peacock SJ, Connors JM, Marra MA, Lynd LD, Marra CA. Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). BMC Health Serv Res. 2013 Oct 31;13(1):454.
- Najafzadeh M, Davis JC, Joshi P, Marra C. Barriers for integrating personalized medicine into clinical practice: A qualitative analysis. Am J Med Genet A. 2013 Apr; 161(4):758-63.
- Sadatsafavi M, Bansback N, Zafari Z, Najafzadeh M, Marra C. Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information. Value Health. 2013 Mar-Apr; 16(2):438-48.
- Najafzadeh M, Marra CA, Lynd LD, Sadatsafavi M, Fitzgerald JM, McManus B, Sin D. Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. PLoS One. 2012; 7(10):e46746.
- Najafzadeh M, Marra CA, Lynd LD, Wiseman SM. Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer. Value Health. 2012 Dec; 15(8):1005-13.
- Najafzadeh M, Lynd LD, Davis JC, Bryan S, Anis A, Marra M, Marra CA. Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. Genet Med. 2012 May; 14(5):520-6.
- Davis JC, Marra CA, Robertson MC, Najafzadeh M, Liu-Ambrose T. Sustained economic benefits of resistance training in community-dwelling senior women. J Am Geriatr Soc. 2011 Jul; 59(7):1232-7.
- Davis JC, Marra CA, Beattie BL, Robertson MC, Najafzadeh M, Graf P, Nagamatsu LS, Liu-Ambrose T. Sustained cognitive and economic benefits of resistance training among community-dwelling senior women: a 1-year follow-up study of the Brain Power study. Arch Intern Med. 2010 Dec 13; 170(22):2036-8.
- Lynd LD, Marra CA, Najafzadeh M, Sadatsafavi M. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. Pharmacoepidemiol Drug Saf. 2010 Nov; 19(11):1172-80.
Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W, Habyarimana J, Sadatsafavi M, Najafzadeh M, Marra CA, Estambale B, Ngugi E, Ball TB, Thabane L, Gelmon LJ, Kimani J, Ackers M, Plummer FA. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010 Nov 27;376(9755):1838-45. Epub 2010 Nov 9.
Lynd LD, Najafzadeh M, Colley L, Byrne MF, Willan AR, Sculpher MJ, Johnson FR, Hauber AB. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making–a case study of alosetron in irritable bowel syndrome. Value Health. 2010 Jun-Jul; 13(4):411-7.
Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009; 27(12):991-1004. View in: PubMed
Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax. 2008 Nov; 63(11):962-7. View in: PubMed
Sadatsafavi M, Najafzadeh M, Lynd L, Marra C. Reliability studies of diagnostic tests are not using enough observers for robust estimation of interobserver agreement: a simulation study. J Clin Epidemiol. 2008 Jul; 61(7):722-7. View in: PubMed